ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

This study is testing a combination of treatments — immunotherapy (sintilimab + IBI305, which blocks blood vessel growth) plus targeted radiation (SBRT) — for people with advanced lung cancer that has a specific EGFR gene mutation and has stopped responding to a third-generation targeted drug (EGFR-TKI). **You may be eligible if...** - You have advanced (stage IV) non-small cell lung cancer confirmed by biopsy - Your cancer has a specific EGFR mutation (L858R or exon 19 deletion) - Your cancer has stopped responding to a third-generation EGFR-targeted drug (such as osimertinib) - You are in good general health (ECOG 0–1) - You have at least one measurable tumor on scans - Your organ function (blood, liver, kidneys) meets the required levels **You may NOT be eligible if...** - You have symptomatic brain metastases or need steroids for brain swelling - Your cancer does not have an EGFR mutation - You have not yet tried an EGFR-targeted therapy Talk to your doctor to see if this trial is right for you.